Ind-Swift Laboratories Ltd. (IN:INDSWFTLAB)
:INDSWFTLAB
Want to see IN:INDSWFTLAB full AI Analyst Report?
INDSWFTLAB Stock Chart & Stats
₹90.70
-₹2.17(-1.99%)
At close: 4:00 PM EST
₹90.70
-₹2.17(-1.99%)
Day’s Range― - ―
52-Week Range₹67.15 - ₹156.50
Previous CloseN/A
Volume31.71K
Average Volume (3M)7.30K
Market Cap
₹11.68B
Enterprise Value₹8.29B
Total Cash (Recent Filing)₹4.33B
Total Debt (Recent Filing)₹220.47M
Price to Earnings (P/E)18.9
Beta1.02
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding86,711,555
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.96
P/FCF Ratio-5.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~25% revenue growth signals expanding product uptake and market share in the company’s core therapeutic areas. Over 2–6 months this supports higher operating scale, potential margin recovery from fixed-cost absorption, and a larger base for reinvestment in R&D and commercial expansion.
Conservative Balance SheetExtremely low leverage and a high ROE provide durable financial flexibility: limited interest burden, capacity to fund capex or acquisitions, and resilience through industry cycles. This structural strength reduces solvency risk and preserves strategic optionality over months ahead.
Industry PositionOperating in specialty and generic pharmaceuticals offers persistent, structural demand, regulatory barriers to entry, and recurring revenue from established molecules. This industry positioning supports multi‑month visibility in revenues and underpins long‑term product lifecycle opportunities.
Bears Say
Cash Flow WeaknessPersistently negative operating and free cash flows indicate weak cash conversion of profits and potential liquidity strain. Over a 2–6 month horizon this can limit self‑funding for working capital, R&D or capex and force reliance on external financing or equity dilution.
Negative EBIT MarginA negative EBIT margin highlights underlying operating profitability issues unrelated to financing or tax items. Structurally, this raises questions about core cost structure, pricing pressure, or product mix, and reduces ability to sustainably generate operating profits in coming months.
Earnings ContractionNegative EPS growth shows earnings per share are contracting, reflecting margin pressure or one‑off impacts. Over a medium horizon, declining EPS can constrain reinvestment, hamper retention of talent, and limit flexibility to return capital to shareholders or fund growth initiatives.
Ind-Swift Laboratories Ltd. News
INDSWFTLAB FAQ
What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?
Ind-Swift Laboratories Ltd. lowest stock price was ₹67.15 and its highest was ₹156.50 in the past 12 months.
What is Ind-Swift Laboratories Ltd.’s market cap?
Ind-Swift Laboratories Ltd.’s market cap is ₹11.68B.
When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?
Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 35 days.
How were Ind-Swift Laboratories Ltd.’s earnings last quarter?
Ind-Swift Laboratories Ltd. released its earnings results on Jan 31, 2026. The company reported ₹1.169 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.169.
Is Ind-Swift Laboratories Ltd. overvalued?
According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued.
Does Ind-Swift Laboratories Ltd. pay dividends?
Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here
What is Ind-Swift Laboratories Ltd.’s EPS estimate?
Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ind-Swift Laboratories Ltd. have?
Ind-Swift Laboratories Ltd. has 86,711,555 shares outstanding.
What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?
Ind-Swift Laboratories Ltd. reported an EPS of ₹1.169 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.07%.
Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:INDSWFTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
Lincoln Pharmaceuticals Ltd
―
Solara Active Pharma Sciences Ltd.
―
Venus Remedies Limited
―